Antegenes
Innovative genetic tests for cancer risks with recommendations for prevention and early detection.
Innovative genetic tests for cancer risks with recommendations for prevention and early detection.
Antegenes is a healthcare technology startup founded in 2018 and based in Estonia. The company focuses on developing and implementing innovative genetic tests utilizing polygenic risk score technology to enable personalized prevention of common cancers. With a slogan of "Innovative genetic tests for cancer risks with recommendations for prevention and early detection," Antegenes aims to revolutionize cancer risk assessment and prevention.
The company recently secured a significant €1.60M investment in a Seed Round at 02 August 2022, backed by notable investors including Timo Rein, Andreas Henn Otsmaa, Peep Vain, and Aare Kurist. This latest investment reaffirms the market's confidence in Antegenes' innovative approach and potential impact on the biotechnology and healthcare industries.
Antegenes' commitment to leveraging genetic testing for personalized cancer prevention aligns with the growing demand for advanced healthcare solutions. Their efforts can not only transform preventive healthcare but also have the potential to drive significant advancements in the biotechnology and health care sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €1.60M | 4 | Timo Rein, Andreas Henn Otsmaa +2 | 02 Aug 2022 |
| Grant | €700.00K | 2 | EIT - European Institute of Innovation and Technology, Enterprise Estonia | 02 Aug 2022 |
| Pre Seed Round | €500.00K | - | 10 Nov 2021 | |
| Angel Round | €250.00K | - | 01 Feb 2018 |
No recent news or press coverage available for Antegenes.
We care about your data, and we'd love to use cookies make your experience better.
